Most cited papers from St. Eugenio Hospital

St. Eugenio Hospital

What are the most cited papers from St. Eugenio Hospital?

The most cited paper from St. Eugenio Hospital is "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS" (Marco Valgimigli et al., 2017), with 3,025 citations. Next come "Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study" (825) and "Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial" (811).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 59 papers. Every paper with more than 175 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS Marco Valgimigli et al. · European Heart Journal Open access154 authors	26 Aug 2017	3,025
2	Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study Michèle Cavo et al. · The Lancet	Dec 2010	825
3	Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial Antonio Palumbo et al. · The Lancet	Mar 2006	811
4	Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson's disease Alessandro Stefani, Andrés M. Lozano, Antonella Peppe et al. · Brain Open access	25 Jan 2007	807
5	Autologous Transplantation and Maintenance Therapy in Multiple Myeloma Antonio Palumbo et al. · New England Journal of Medicine Open access	3 Sep 2014	786
6	Locomotor Primitives in Newborn Babies and Their Development Nadia Dominici, Yuri P. Ivanenko, Germana Cappellini et al. · Science	17 Nov 2011	683
7	Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia Giampaolo Bucaneve, Alessandra Micozzi, Francesco Menichetti et al. · New England Journal of Medicine Open access	7 Sep 2005	650
8	Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial Jörge E. Cortes et al. · Blood Open access	22 Mar 2018	598
9	Impaired Cerebral Vasoreactivity and Risk of Stroke in Patients With Asymptomatic Carotid Artery Stenosis Mauro Silvestrini · JAMA	26 Apr 2000	592
10	Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura Roberto Stasi, Adalberto Pagano, Elisa Stipa et al. · Blood	15 Aug 2001	551
11	Treatment of Relapsing Mild-to-Moderate Ulcerative Colitis With the Probiotic VSL#3 as Adjunctive to a Standard Pharmaceutical Treatment: A Double-Blind, Randomized, Placebo-Controlled Study Antonio Tursi et al. · The American Journal of Gastroenterology Open access	Jun 2010	495
12	Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial Carlo Di Mario, Dariusz Dudek, Federico Piscione et al. · The Lancet	Feb 2008	439
13	Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell–depleting therapy with rituximab Roberto Stasi, Nichola Cooper, Giovanni Del Poeta et al. · Blood	29 Mar 2008	410
14	Factors associated with outcomes of unrelated cord blood transplant: Guidelines for donor choice Éliane Gluckman et al. · Experimental Hematology Open access	30 Mar 2004	395
15	Maintenance Treatment with Recombinant Interferon Alfa-2b in Patients with Multiple Myeloma Responding to Conventional Induction Chemotherapy Franco Mandelli, Giuseppe Avvisati, Sergio Amadori et al. · New England Journal of Medicine Open access	17 May 1990	385
16	Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients Wilma Barcellini et al. · Blood Open access	18 Sep 2014	380
17	Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase François Guilhot, Jane F. Apperley, Dong‐Wook Kim et al. · Blood Open access	30 Jan 2007	374
18	Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial Antonio Palumbo, Sara Bringhen, Anna Marina Liberati et al. · Blood Open access	27 May 2008	359
19	Long-Term observation of 208 adults with chronic idiopathic thrombocytopenic purpura Roberto Stasi, Elisa Stipa, Mario Masi et al. · The American Journal of Medicine	May 1995	355
20	Shared Genetic Susceptibility to Ischemic Stroke and Coronary Artery Disease Martin Dichgans et al. · Stroke Open access	22 Nov 2013	343
21	Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML) Giovanni Del Poeta, Adriano Venditti, Maria Ilaria Del Principe et al. · Blood	27 Feb 2003	341
22	Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial Francesca Gay et al. · The Lancet Oncology Open access	16 Nov 2015	316
23	Efficacy of Atorvastatin Reload in Patients on Chronic Statin Therapy Undergoing Percutaneous Coronary Intervention Germano Di Sciascio, Giuseppe Patti, Vincenzo Pasceri et al. · Journal of the American College of Cardiology Open access	3 Jul 2009	316
24	Response to B-cell–depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura Roberto Stasi, Giovanni Del Poeta, Elisa Stipa et al. · Blood Open access	4 Jun 2007	300
25	The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy Florian Heinen et al. · European Journal of Paediatric Neurology Open access	16 Nov 2009	296
26	LPI-labile plasma iron in iron overload Zvi Ioav Cabantchik, W. Breuer, Giuliana Zanninelli et al. · Best Practice & Research Clinical Haematology	26 Feb 2005	295
27	Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia Philipp le Coutre et al. · Blood Open access	30 Nov 2007	292
28	A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum Vito Lorusso, C. F. Pollera, Mauro Antimi et al. · European Journal of Cancer	Jul 1998	289
29	Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide Alessandra Larocca et al. · Blood	12 Aug 2011	289
30	Functional Mineralocorticoid Receptors in Human Vascular Endothelial Cells Regulate Intercellular Adhesion Molecule-1 Expression and Promote Leukocyte Adhesion Massimiliano Caprio, Brenna G. Newfell, Andrea Sala et al. · Circulation Research Open access	8 May 2008	284
31	Idiopathic thrombocytopenic purpura: Current concepts in pathophysiology and management Maria Laura Evangelista, Elisa Stipa, Francesco Buccisano et al. · Thrombosis and Haemostasis Open access	14 Dec 2007	277
32	Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials Peter M. Fayers, Antonio Palumbo, Cyrille Hulin et al. · Blood Review	14 Jun 2011	274
33	Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients Francesca Gay et al. · Blood Open access	12 Jan 2011	267
34	Chitin nanofibrils/chitosan glycolate composites as wound medicaments Riccardo A.A. Müzzarelli, Pierfrancesco Morganti, Gianluca Morganti et al. · Carbohydrate Polymers	21 Apr 2007	266
35	Normal weight obese (NWO) women: An evaluation of a candidate new syndrome Antonino De Lorenzo, Roberta Martinoli, F. Vaia et al. · Nutrition Metabolism and Cardiovascular Diseases	4 Mar 2006	264
36	Beneficial Long-Term Effects of Combined Oral/Topical Antioxidant Treatment with the Carotenoids Lutein and Zeaxanthin on Human Skin: A Double-Blind, Placebo-Controlled Study Paolo Palombo, Giuseppe Fabrizi, Vincenzo Ruocco et al. · Skin Pharmacology and Physiology	2007	252
37	Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial Francesca Gay et al. · The Lancet Oncology	11 Nov 2021	251
38	Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia Valter Gattei, Pietro Bulian, Maria Ilaria Del Principe et al. · Blood Open access	24 Oct 2007	249
39	Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Antonio Tursi, Giovanni Brandimarte, Gian Marco Giorgetti et al. · PubMed	Nov 2004	243
40	A randomized trial comparing ReCell® system of epidermal cells delivery versus classic skin grafts for the treatment of deep partial thickness burns Gianpiero Gravante, M.C. Di Fede, Antonino Araco et al. · Burns	Oct 2007	231
41	GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia Adriano Venditti et al. · Blood Open access	8 Aug 2019	221
42	Best Practices for the Prevention of Radial Artery Occlusion After Transradial Diagnostic Angiography and Intervention Ivo Bernát, Adel Aminian, Samir Bipin Pancholy et al. · JACC: Cardiovascular Interventions Open access	Nov 2019	212
43	Age and d PCR can predict relapse in CML patients who discontinued imatinib: The ISAV study Silvia Mori et al. · American Journal of Hematology Open access	15 Jul 2015	212
44	The nutritional risk in oncology: a study of 1,453 cancer outpatients The SCRINIO Working Group et al. · Supportive Care in Cancer Open access	6 Feb 2012	210
45	Predictors of high level of burden and distress in caregivers of demented patients: results of an Italian multicenter study P. Rinaldi et al. · International Journal of Geriatric Psychiatry	19 Jan 2005	198
46	Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study Michele Baccarani et al. · Blood	5 Mar 2009	197
47	Glyceryl trinitrate for chronic anal fissure—Healing or headache? Donato F. Altomare, Marcella Rinaldi, Giovanni Milito et al. · Diseases of the Colon & Rectum	Feb 2000	196
48	Deferiprone versus Deferoxamine in Patients with Thalassemia Major: A Randomized Clinical Trial Aurelio Maggio, Gennaro D’Amico, Alberto Morabito et al. · Blood Cells Molecules and Diseases	Mar 2002	192
49	Risk of de novo cancers after transplantation: Results from a cohort of 7217 kidney transplant recipients, Italy 1997–2009 Pierluca Piselli, Diego Serraino, Giuseppe Segoloni et al. · European Journal of Cancer	11 Oct 2012	190
50	Anatomic Basis and Physiological Rationale of Distal Radial Artery Access for Percutaneous Coronary and Endovascular Procedures Gregory Angelo Sgueglia, Angela Di Giorgio, Achille Gaspardone et al. · JACC: Cardiovascular Interventions Open access	Oct 2018	188

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.